Trials / Completed
CompletedNCT00725348
An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis
An Open-Label, Multi-Center Pilot Trial to Assess the Efficacy and Safety of Oral R115866 in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Stiefel, a GSK Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of a new oral drug used for the treatment of psoriasis. All subjects will get active medication, there is no placebo arm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talarozole | 1.0 mg oral dose per day |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2005-03-01
- Completion
- 2006-12-01
- First posted
- 2008-07-30
- Last updated
- 2011-09-26
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00725348. Inclusion in this directory is not an endorsement.